Lexaria Expands Scope with National Research Council Agreement
Ryan Allway
February 13th, 2017
News, Top News
Lexaria Corp. (OTCQB: LXRP) has been quietly developing an innovative delivery system that has the potential to revolutionize several industries. By encapsulating active ingredients in a lipid, the technology enhances the bioavailability of the active compound by facilitating it into the intestinal tract while eliminating any negative tastes or textures. The technology is patent-pending for use with both cannabinoids and anti-inflammatory drugs (“NSAIDS”).
In this article, we will take a look at the company’s collaboration with the National Research Council of Canada and its potential over the coming years.
Expand Scope of Research
Lexaria’s master collaborative research agreement with the National Research Council of Canada (“NRC”) opens several doors for its innovative delivery technology. For example, the company does not have the permits needed to explore the potential implications of its technology on tetrahydrocannabinol (“THC”) related products. The NRC is a governmental organization that has the rights to work with THC and other controlled substances.
“This co-funded research agreement with the National Research Council of Canada is a major achievement for us,” said Lexaria President John Docherty in a press release announcing the collaboration. “Having the privilege to work within their high caliber facilities alongside their expert scientists will allow Lexaria to further advance the characterization and commercial potential of its technology in the fastest way possible for a company of our size.”
The agreement also provides funding to better understand how the technology works to improve bioavailability. Under the terms, Lexaria and the NRC will both provide up to C$125,000 in funding for a total investment of up to C$250,000 over 18 months. The collaboration will investigate and define the chemical nature of the molecular association that the technology leverages in order to increase the bioavailability of various substances.
Potential Licensing Opportunities
The researchers will evaluate cannabinoids (including THC), fat-soluble vitamins, non-steroidal anti-inflammatory drugs, and nicotine, as described in Lexaria’s issued and pending patent applications, and could grow that list with other high value bioactives to be determined. The agreement also provides for possible licensing of any arising, non-competing intellectual property to the NRS or its sub-licensees on terms to be defined in the future.
“The National Research Council’s support in the development and commercialization of our technology is highly validating for our company,” said Lexaria CEO Chris Bunka in the same press release. “Positive findings from this joint investigation will be of tremendous value to Lexaria in order to broaden the scientific understanding of our intellectual property suite and support our abilities to attract additional strategic licensees.”
Management sees the potential to attract licensees across several end markets, including the therapeutic foods, dietary supplements, and pharmaceutical sectors. Through these markets, the company could launch a wide range of products to consumers including over-the-counter pain remedies, vitamins and supplements, and even smoking cessation products. Combined, these markets represent billions of dollars in potential revenue.
Looking Ahead
Lexaria Corp.’s (OTCQB: LXRP) research agreement with the NRC marks a key milestone in the company’s corporate history. By better understanding its technology and evaluating its use on controlled substances, the company is setting the stage for potential licensing opportunities through the NRC and leveraging the research produced through the collaboration. The agreement also brings validation to a small company such as Lexaria, working to introduce its technology in a newly crowded market. Investors may want to keep an eye on the stock given these near-term catalysts.
For more information, visit the company’s website or CannabisFN’s company profile.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Aleafia, a vertically integrated, national cannabis company, operates major medical clinic, cannabis cultivation and R&D facilities.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
